Increased NY-ESO-1 Expression and Reduced Infiltrating CD3+ T Cells in Cutaneous Melanoma
Table 1
Clinical and histopathological parameters in NY-ESO-1 positive and negative primary cutaneous melanomas.
Parameter
Subgroup
Number of patients (%)
NY-ESO-1 (+)
NY-ESO-1 (−)
(%)
(%)
Gender
Male
31 (40)
8 (26)
23 (74)
Female
47 (60)
8 (17)
39 (83)
Skin phototype
I
1 (2)
0 (0)
1 (100)
II
35 (56)
7 (20)
28 (80)
III
22 (35)
5 (22)
17 (78)
IV
4 (6)
2 (50)
2 (50)
V
2 (3)
0 (0)
2 (100)
VI
1 (2)
0 (0)
1 (100)
Median age (years)
78
55.2
58.3
Location
Extremity
28 (35)
6 (21)
22 (79)
Trunk
29 (37)
6 (21)
23 (79)
Head and neck
14 (18)
1 (7)
13 (93)
Acral (Hand and foot)
8 (11)
3 (37.5)
5 (62.5)
Melanoma subtype
Superficial spreading
31 (39)
2 (6)*
29 (94)*
Nodular
26 (33)
6 (23)
20 (77)
Lentigo maligna
7 (9)
3 (43)
4 (57)
Acral lentiginous
8 (10)
3 (37.5)
5 (62.5)
Unclassified
7 (9)
2 (29)
5 (71)
Ulceration
Present
16 (20)
5 (31)
11 (69)
Absent
63 (80)
11 (17)
52 (83)
Breslow#
≤1.0 mm
24 (30)
2 (8)
22 (92)
1.01–2.0 mm
23 (29)
3 (13)
20 (87)
2.01–4.0 mm
6 (8)
3 (50)
3 (50)
>4.0 mm
26 (33)
8 (31)
18 (69)
Sentinel lymph node
Positive
2 (11)
0 (0)
2 (100)
Negative
16 (89)
4 (25)
12 (75)
Follow-up
Disease-free
37 (54)
10 (27)
27 (73)
Alive with metastases
14 (21)
2 (14)
12 (86)
Dead of melanoma
14 (21)
2 (14)
12 (86)
Lost
3 (4)
2 (67)
1 (33)
NY-ESO-1 (+): NY-ESO-1 positive; NY-ESO-1 (−): NY-ESO-1 negative; *P < 0.02 for superficial spreading compared to other primary tumor types; #P value was not significant when Breslow index was analyzed as a categorical variable (groups); however, P = 0.017 when Breslow index was analyzed as a continous variable.
